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We hereby provide a two-year update on the HUPO Human Plasma Proteome
Project (HPPP) informed by advances presented at the HPPP sessions at the
HUPO World Congresses in Toronto in September 2009 and in Sydney in
September 2010.
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The 2009 HPPP1HCVI Workshop at the Toronto HUPO
Congress
The 2009 Workshop was an experiment in co-scheduling two HUPO Initiatives,
the HPPP and HUPO CardioVascular Initiative. The organizers, chairs Peipei
Ping and Gil Omenn, aimed to stimulate interactions among the speakers and
the attendees, which was successful.
Terry Farrah of the Institute of Systems Biology gave a 2009 update for the
Human Plasma PeptideAtlas, expanding the 2005 HPPP reports [1] and the
initial Human Plasma PeptideAtlas of 2007 (www.peptideatlas.org). Shotgun
MS/MS data sets were re-analyzed from raw spectra with the Trans Proteomic
Pipeline (TPP), searching with SpectraST for non-glyco and with X!Tandem for
glycoprotein data. The Human Plasma PeptideAtlas, including N-glyco- and
Non-glyco-subatlases, can be used conveniently to check whether proteins
identified in tissues, or in new plasma or serum studies, have been identified
previously in plasma and what specific peptides and spectra have been observed.
Several enhancements to Peptide Atlas were described as under development:
more sophisticated statistical modeling with iProphet to drive down protein false
discovery rates (FDR); decoy searches to facilitate estimation of protein FDR
using Mayu; multi-level protein identifications to reduce redundancy; and esti-
mated abundance from spectral counting and quantitative immunoassay data.
iProphet and decoy searches are inserted between PeptideProphet and Protein-
Prophet in the TPP. The Human Plasma PeptideAtlas was populated first with
HPPP-I data sets and expanded with academic and corporate submissions.
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HPPP-II increments from the Smith Lab at Pacific Northwest/Battelle and
N-glyco-data sets from others boosted the cumulative protein identifications. At
o1% protein FDR, the number of protein matches recognized can be reduced
from 8314 sequence specific to 4334 peptide-set-unique to 2462 distinguishable
to 2050 covering set to 1986 canonical. In PeptideAtlas these adjectives appear in
the column ‘‘presence level.’’ This range illustrates how hard it is to compare
numbers of protein identifications processed with different rules and different
tolerances for potential redundancy. Regardless, the greater the protein sequence
coverage, the lesser the ambiguity of peptide-to-protein matches. A detailed
publication of these PeptideAtlas enhancements and updates has now been
published [2].
Henning Hermjakob of the European Bioinformatics Institute and Eric
Deutsch of the Institute for Systems Biology described progress toward the
ProteomeXchange that will link primary data repositories at EBI/PRIDE and the
then-new NIH/Peptidome via the distributed file-sharing system Tranche at
www.proteomecommons.org, developed at the University of Michigan, and then
to systematic reanalysis at ISB/PeptideAtlas in Seattle and at GPMDB in
Winnipeg. Unfortunately, currently, due to budget pressures, NIH has termi-
nated Peptidome and Tranche is stressed by very high data set load and limited
staffing.
From the ETH-Zurich Aebersold Laboratory, Bernd Wollscheid highlighted
progress on proteotypic peptides and selected reaction monitoring (SRM) for
plasma. This approach provides a strategy and N-glycosite peptide reagents for
quantitative identification of targeted peptides. Glycoproteins represent an espe-
cially informative subproteome, enriched for cell surface and secreted proteins.
Because albumin is not a glycoprotein, this strategy reduces complexity and
enhances dynamic range. Meanwhile, more than 80% of FDA-approved clinical
marker assays are glycoprotein analytes. Since the early adaptation of MRM by
Leigh Anderson and Christie Hunter (Applied Bio), there has been rapid emer-
gence and availability of QQQ mass spectrometers and software to guide the choice
of peptides with favorable ionization and generation of distinctive transitions in the
third quadrupole at scheduled retention times. Wollscheid discussed how to select
the proteins and their peptides for SRM assay development and how to generate
and optimize the SRM assays. PeptideAtlas and UniPep (human N-linked glyco-
sites) are key databases. Synthetic peptides can be produced on solid-stage
substrates from which they are released by chemical cleavage for use in SRM assays
(e.g. JPT, Berlin). ETHZ has produced a library of SRM spectra for the entire yeast
proteome [3], and is rapidly generating 5000 peptides for 2300 proteins from the
human N-glycosite proteome.
Rajasree Menon of the University of Michigan presented an analytical frame-
work for the detection and annotation of alternative splice variant peptides, a new
class of isoform-specific protein cancer biomarkers in plasma and tumors. Alter-
native splicing generates protein diversity without increasing genome size. The
analytical pipeline identifies and quantifies known and novel splice isoforms from
peptide sequences determined by LC-MS/MS. MS/MS spectra are interrogated
against a non-redundant database of exhaustive three-frame translation of
Ensembl transcripts and gene models from ECgene using the X!Tandem software.
The search results are processed for peptide-to-protein integration by TPP and
Michigan Peptide-to-Protein Integration (MPPI) [4]. Over-expressed novel variants
are validated by qRT-PCR. The exact splicing findings and the biological annota-
tions for differentially expressed splice variant proteins in pancreatic, breast, and
colon cancers are quite interesting.
Jennifer Van Eyk of Johns Hopkins University illustrated the application of
proteomics in cardiovascular diseases with a focus on aortic aneurysms. Aortic
dissection, resulting from a tear in the aorta, is associated with a mortality rate of
1% per hour without surgical intervention. Aortic dissection can be caused by
3440 G. S. Omenn et al. Proteomics 2011, 11, 3439–3443
& 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
multiple mechanisms, including inherited connective tissue disorders, like
Marfan syndrome (MFS, a result of genetic defects in fibrillin 1). Proteomics
have been applied to investigate both the natural history and MFS disease. 2-DE
and MS-based iTRAQ quantification of aortic tissue obtained from young and
old rats indicated numerous secreted proteins were increased, including the
glycoprotein MFG-E8, which was shown to alter smooth muscle cells via a novel
interplay with Ang II [5]. Quantification of MFG-E8 along with other age-related
secreted proteins (like TGF-b1) has potential to determine ‘‘biological age’’ and
associated risk for cardiovascular disease also in humans. In fact, the quantita-
tion of circulating levels in the mouse model of MFS showed that TGF-b1 may
allow assessment of the activity of aortic aneurysms and was sensitive to therapy
with losartan, an AT1-inhibitor that significantly decreases aortic diameter in
MFS patients. TGF-b1 was verified as a potential marker in the GenTac patient
registry that enrolls patients with aortic aneurysms from a broad spectrum of
heritable cardiac diseases and syndromes [6]. Mingning Ning of Massachusetts
General Hospital and Harvard Medical School in Boston discussed how the
brain–heart connection can lead to various neurovascular disease states. An
extreme version of the influence of the brain on heart functions occurs when
people are literally ‘‘scared to death" resulting, most likely, from a massive
catecholamine surge. Conversely, the heart can influence and induce neuro-
vascular injury. Dr. Ning’s laboratory concentrates on the underlying mechan-
isms in cardiac structural abnormalities, such as patent foramen ovale (PFO),
which can lead to embolic strokes. Using direct bedside intra-cardiac plasma
sampling and quantitative temporal protein profiling of patients undergoing
PFO closure, her team has been able to discern some of the underlying
physiological mechanisms. Analyses of the plasma microparticle sub-proteome
has been useful in mapping the important brain–heart interactions in such
neurovascular injuries.
Michael Kuzyk of the University of Victoria in British Columbia, Canada
presented data on plasma-based SRM assays for 45 analytes, which were selected
as potential biomarkers specifically to be able to distinguish patients with coronary
artery disease from normal control subjects. Peptide standards were created for
each SRM assay allowing absolute quantitation of the analytes from tryptic digests
of human EDTA-plasma without prior affinity depletion or enrichment. To
achieve maximal sensitivity and specificity, instrument parameters were adjusted
to generate the most abundant precursor ions and y ion fragments. Excellent
linear responses (r 40.99) were obtained for 43 of the 45 proteins, with attomole
level limits of quantitation and o20% coefficient of variation for 27 of the 45
proteins and with analytical precision for 44 of the 45 assays, varying by o10% [7].
Concentrations for 39 of the 45 proteins were within a factor of 2 of the reported
literature values based on ELISAs.
The 2010 HPPP Workshop Session in the Sydney HUPO
Congress
Eric Deutsch of the Institute for Systems Biology provided an update on the
Human Plasma PeptideAtlas. Currently, there are approximately 2000 distin-
guishable, canonical proteins with a protein FDR of 1%, the largest high-
confidence proteome compiled to date (note 2009 Human Plasma PeptideAtlas
update above). Spectra came from 69 conventional LC-MS/MS-based plasma
proteome studies and from 22 studies in which tryptic peptides isolated via solid-
phase glycocapture were searched against a target-decoy sequence database
using the X!Tandem [1]. All peptide-spectrum matches (PSMs) were
assigned probabilities using the TPP statistical validation tools. Spectra for each
experiment below a given PSM FDR (0.0002 for non-glycocapture, 0.00003 for
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glycocapture) were compiled. FDRs were decoy-estimated at 1% for proteins and
0.16% for peptides, lower than previously reported human plasma peptide lists.
He showed how these data can be leveraged by the PeptideAtlas query tools to
enable targeted proteomics via SRM mass spectrometry.
At the Human Proteome Project (HPP) launch session of the 2010 HUPO
Congress, Deutsch presented data from Laura Beretta, Tadashi Yamamoto, and
Gil Omenn from preliminary cross-proteome analyses for the HUPO liver,
kidney, urine, and plasma initiatives. These and other HUPO initiatives are one
of the foundations for the biology and disease-driven component of the Human
Proteome Project (B/D-HPP) [8].
Richard Lipscombe of Proteomics International and the Centre for Food and
Genomic Medicine in Perth, Western Australia, spoke about ‘‘diabesity,’’ a term
that combines the twin epidemics of diabetes and obesity, and is considered to be
a ‘‘metabolic time bomb.’’ In the last decade, numbers of diabetics worldwide
have doubled and are projected to grow from 250 to 380 million by 2015. Plasma
biomarkers are being sought for prediction of early-onset of diabesity and its
complications, and ultimately to facilitate discovery of new therapeutic targets.
Ten cohorts representing diverse Western Australian populations have been
studied, including both children and adults with either type 1 or type 2 diabetes
or who are obese. This group also has gained access to the Busselton Health
Study (16 000 participants) and the Fremantle Diabetes Study (1426 partici-
pants). Plasma samples from selected subgroups of various cohorts have been
quantified using iTRAQ following immunodepletion, analysis by LC-MALDI-
MS/MS, and then validation. Candidate biomarkers using an orthogonal MRM
approach. Between 200 and 300 proteins per cohort were identified; across all
studies 60 proteins showed significant differences in expression when compared
to controls, of which two-third were new associations.
Richard Smith of the Pacific Northwest National Laboratory (PNNL) in Rich-
land, Washington, USA, described several emerging proteomics technologies that
are highly promising. These discovery-based tools are able to measure thousands
of proteins in plasma and other complex biological samples and represent a
technical breakthrough. Success to date in establishing new clinical biomarkers
has been limited, in general, despite such significant technological advances and
large investments in biomarker discovery efforts. One explanation is that current
proteomic technologies have not provided sufficient sensitivity for broad coverage
of the proteome in combination with the throughput required for confident
biomarker discovery applications. This is further complicated by the extent of
human biological variation, the large dynamic range of protein abundances in
blood, and the sensitivity needed to detect many clinically relevant analytes that are
expected to be present in low ng/mL to pg/mL concentrations. As part of the NIH-
supported Proteomics Research Center at PNNL, Dr. Smith’s group has developed
a nano-liquid chromatography-ion mobility MS proteomics platform that provides
significantly improved sensitivity and a throughput of 450 samples per day.
Examples were provided that illustrated the best currently available platforms with
a variety of discovery and verification studies.
Bernd Wollscheid of the Institute for Molecular Systems Biology at ETH-Zurich
presented platforms for sensitive, reproducible MS-based measurements, primarily
an update on SRM platforms. N-Glycosylated proteins represent a clinically inter-
esting subproteome which by SRM can achieve low ng/mL limits of detection
without prior sample fractionation. Dr. Wollscheid presented data on a new library
of verified SRM assays and associated tools for 7000 N-glycosites that are mapped to
3298 human proteins [9]. The parameters for these SRM assays are available
through the new public resource freely accessible through the SRMAtlas web-
repository. SRMAtlas will enable faster design and implementation of quantitative
SRM-based experiments by providing tested SRM peptide measurement coordinates
for a wide range of clinical research questions. Examples were provided on the
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quantification of 53 selected glycoproteins spanning almost seven orders of
magnitude in concentration in sera from 32 individual donors.
We anticipate that the progress from such studies of the human plasma
proteome will be a good foundation for the HPP and many other basic and
clinical applications.
The authors thank all the speakers and participants in these workshops, Peipei Ping
and Jennifer Van Eyk for providing summaries of the Ning and Van Eyk presentations,
and Sylvie Ouellette for coordinating communications with all the HUPO initiatives
from HUPO HQ.
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